AbbVie, Bristol Myers Squibb and Eli Lilly appear “relatively well-positioned,” while Novartis and Roche look more at risk, ...

Swiss drugmaker Novartis will pay up to $1 billion to U.S. biotech Matchpoint Therapeutics to develop oral drugs for several ...

Incyte Corp (INCY) reports a 17% increase in total product revenues and raises full-year guidance amid robust demand and ...

The record-setting Alexandria lab lease in San Diego showcases how biotech has few big tenants left to take empty spaces.

Novartis and its Fabhalta may have been first to the punch in ultrarare kidney disease complement 3 glomerulopathy (C3G), but ...

Novartis is serving up $60 million to partner with Matchpoint Therapeutics in hopes of getting an oral covalent inhibitor ...

Matchpoint Therapeutics partners with Novartis to develop oral covalent inhibitors for inflammatory diseases, with potential ...

Novartis and Matchpoint Therapeutics have entered into a partnership worth $1bn to develop oral inhibitors for inflammatory ...

The MoU, which aims to enhance cancer care, broaden cardiology collaboration, and promote medical training, has seen ...

Matchpoint to receive up to $60 million in upfront payment and research funding, with up to $1 billion in total potential ...